18 December 2023
Nuformix plc
("Nuformix" or the "Company")
NXP001 Update
Nuformix receives second NXP001 milestone payment from Oxilio
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that the Company has achieved the second milestone according to its updated NXP001 exclusive licensing agreement with Oxilio Ltd ("Oxilio") and received the associated payment.
Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: "Oxilio is progressing NXP001 with Nuformix's full support. We are pleased to have triggered the second milestone payment as per the terms of our updated agreement. Funds received continue to assist in advancing our core NXP002 and NXP004 programmes as we progress partnering interactions for these programmes."
Enquiries:
|
Nuformix plc |
|
|
Dr Dan Gooding, Executive Director |
Via IFC Advisory |
|
Stanford Capital Partners Limited |
|
|
Tom Price / Patrick Claridge (Corporate Finance) |
+44 (0) 20 3650 3650 |
|
Bob Pountney (Corporate Broking) |
+44 (0) 20 3650 3652 |
|
IFC Advisory Limited |
|
|
Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6630 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.